HER2 Amplification LPS001 - Detail

The HER2 human epidermal growth factor receptor gene (ERBB2 or NEU), located at 17q11-12 is a member of the EGF (epidermal growth factor) receptor family¹. It is activated and amplified in 20-30% of breast cancers² and it has been correlated with a poor prognosis for the patient. Monoclonal antibody treatment of amplification patients using Herceptin (Trastuzumab) is effective, increasing the survival time by specifically targeting cells that overexpress the HER2 protein³ and cleaning them from the system. Similar results have been obtained for a variety of other malignant neoplasms overexpressing HER2 in cancers e.g. ovary⁴, stomach⁵, salivary gland⁶ and in small cell lung cancer⁷.

Reference:/Bibliographie/Literatur/Bibliografia

1. Yang-Feng et al. 1985
2. Slamon DJ et al. 1987 Science 235:177-182 and 1989 Science 244: 707-712
3. Kauraniemi P et al. 2004 Oncogene 23: 1010-1013
4. Slamon et al 1989
5. Gravalos C, Jimeno A. 2008 Ann Oncol. 19(9): 1523-9
6. Vidal L et al. 2009 Head Neck. Mar 23
7. Sozzi G et al. 1991 Cancer Res 52: 6079-6082